Large-scale population analysis reveals an extremely low threshold for "non-healthy" alanine aminotransferase that predicts diabetes mellitus

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 10, 2010, Pages 1687-1691

  Shlomai, Amir ^a   Kariv, Revital ^a   Leshno, Moshe ^a   Beth Or, Anat ^b   Sheinberg, Bracha ^b   Halpern, Zamir ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b MACCABI HEALTHCARE SERVICES   (Israel)

Author keywords

diabetes mellitus; healthy alanine aminotransferase; liver; normal alanine aminotransferase

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; TRIACYLGLYCEROL; GLUCOSE; HEMOGLOBIN A1C;

AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; DIABETES MELLITUS; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PREDICTOR VARIABLE; PRIORITY JOURNAL; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; ADULT; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DIABETOGENESIS; DISEASE COURSE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HEMOGLOBIN BLOOD LEVEL; MALE; MIDDLE AGED; PREDICTIVE VALUE; RISK ASSESSMENT;

EID: 77957563723     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06369.x     Document Type: Article

References (23)

1. Krier M, Ahmed A. The asymptomatic outpatient with abnormal liver function tests. Clin. Liver Dis. 2009 13 : 167 177.
2. Theal RM, Scott K. Evaluating asymptomatic patients with abnormal liver function test results. Am. Fam. Physician 1996 53 : 2111 2119.
3. Dutta A, Saha C, Johnson CS, Chalasani N. Variability in the upper limit of normal for serum alanine aminotransferase levels: a statewide study. Hepatology 2009 50 : 1957 1962.
4. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ 2005 172 : 367 379.
5. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N. Engl. J. Med. 2000 342 : 1266 1271.
6. Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology 2003 124 : 248 250.
7. Hay JE, Czaja AJ, Rakela J, Ludwig J. The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology 1989 9 : 193 197.
8. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am. J. Gastroenterol. 2009 104 : 861 867.
9. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr., Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 2005 54 : 3140 3147.
10. Monami M, Bardini G, Lamanna C et al. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism 2008 57 : 387 392.
11. Sattar N, Scherbakova O, Ford I et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 2004 53 : 2855 2860.
12. Schindhelm RK, Dekker JM, Nijpels G et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007 191 : 391 396.
13. Vozarova B, Stefan N, Lindsay RS et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002 51 : 1889 1895. (Pubitemid 34564303)
14. Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005 28 : 2913 2918.
15. Goessling W, Massaro JM, Vasan RS, D'Agostino RB, Sr., Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008 135 : 1935 1944, 44 e1.
16. Chodick G, Heymann AD, Shalev V, Kookia E. The epidemiology of diabetes in a large Israeli HMO. Eur. J. Epidemiol. 2003 18 : 1143 1146.
17. Shalev V, Chodick G, Bialik M, Green MS, Heymann AD. In a population-based cohort of diabetes patients, men and women had similar risks for all-cause mortality. J. Clin. Epidemiol. 2007 60 : 86 93.
18. Kariv R, Leshno M, Beth-Or A et al. Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study. Liver Int. 2006 26 : 445 450.
19. Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007 132 : 2191 2207.
20. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005 365 : 1415 1428.
21. Piton A, Poynard T, Imbert-Bismut F et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 1998 27 : 1213 1219.
22. Prati D, Taioli E, Zanella A et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med. 2002 137 : 1 10.
23. Mason JE, Starke RD, Van Kirk JE. Gamma-glutamyl transferase: a novel cardiovascular risk biomarker. Prev. Cardiol. 2010 13 : 36 41.